These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathophysiology of left ventricular hypertrophy in dialysis patients. London GM; Guerin AP; Marchais SJ Blood Purif; 1994; 12(4-5):277-83. PubMed ID: 7865187 [TBL] [Abstract][Full Text] [Related]
3. Left ventricular alterations and end-stage renal disease. London GM Nephrol Dial Transplant; 2002; 17 Suppl 1():29-36. PubMed ID: 11812909 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of cardiovascular disease in hemodialysis patients. Meeus F; Kourilsky O; Guerin AP; Gaudry C; Marchais SJ; London GM Kidney Int Suppl; 2000 Aug; 76():S140-7. PubMed ID: 10936811 [TBL] [Abstract][Full Text] [Related]
5. [Diastolic dysfunction in chronic renal failure patients under hemodialysis]. Douchet MP; Couppie P; Chantrel F; Kuntz C; Hannedouche T Ann Cardiol Angeiol (Paris); 1996 Dec; 45(10):589-92. PubMed ID: 9033698 [TBL] [Abstract][Full Text] [Related]
6. The impact of arteriovenous fistulae on the myocardium: the impact of creation and ligation in the transplant era. Duque JC; Gomez C; Tabbara M; Alfonso CE; Li X; Vazquez-Padron RI; Asif A; Lenz O; Briones PL; Salman LH Semin Dial; 2015; 28(3):305-10. PubMed ID: 25267110 [TBL] [Abstract][Full Text] [Related]
8. Cardiac hypertrophy and arterial alterations in end-stage renal disease: hemodynamic factors. London GM; Marchais SJ; Guerin AP; Metivier F; Pannier B Kidney Int Suppl; 1993 Jun; 41():S42-9. PubMed ID: 8320946 [TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Schmid H; Schiffl H; Lederer SR Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032 [TBL] [Abstract][Full Text] [Related]
10. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J; Koch KM Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence? Wang AY; Li PK; Lui SF; Sanderson JE Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049 [TBL] [Abstract][Full Text] [Related]
13. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Doenst T; Pytel G; Schrepper A; Amorim P; Färber G; Shingu Y; Mohr FW; Schwarzer M Cardiovasc Res; 2010 Jun; 86(3):461-70. PubMed ID: 20035032 [TBL] [Abstract][Full Text] [Related]
14. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival? Covic A; Voroneanu L; Goldsmith D Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478 [TBL] [Abstract][Full Text] [Related]